Y-mAbs cuts 35% of staff; Genentech re-ups Nimble deal; Landos shifts focus; and more
A month after the FDA rejected its neuroblastoma drug, the biotech Y-mabs said it will cut 35% of its workforce to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
